BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap, no noise, just what matters.
Tuesday, November 10, 2026
📌 TL;DR
Argenx agreed to buy Unnatural Products for $550 million upfront plus milestone based contingent value rights, up to approximately $1.15 billion in total, adding an AI guided oral macrocyclic peptide platform; closing is expected by year end.
The FDA issued a Not Approvable Letter on Novocure's Optune Mya in brain metastases from non small cell lung cancer, citing uncertainty about the degree of clinical benefit and raising no safety concerns, per the company.
Veradermics' 12 month Study 302 data showed men on twice daily VDPHL01 gained 43.9 nonvellus hairs per square centimeter, with no treatment related serious adverse events reported.
Novartis said nine Zolgensma patients later developed tumors, two with evidence of vector integration, and the FDA said it is weighing whether regulatory action is appropriate, per BioPharma Dive.
Tape: VIR +11.8% on the pivotal win, NVCR −5.6% on the FDA letter, XBI +3.1%.
⚡ Executive Takeaway
An antibody company just paid $550 million in cash for the right to make pills, and that tells you who funds discovery in this market. Not public investors. They keep paying for things they can count, a pivotal win, a dated filing, and they keep taxing surprise. The money for uncountable things now comes from strategics with a franchise throwing off cash. Argenx is spending Vyvgart's profits on a Santa Cruz lab that could never have priced an IPO on preclinical macrocycles, and it is buying the engine outright rather than licensing one molecule at a time. That is the certainty premium's mirror image: when the market refuses to price optionality, whoever can afford to wait buys it at a private price. Monday graded the public half of our through line cleanly. Vir's first session outran a strong sector by nearly nine points, while Novocure fell into a rally once the FDA said its trial did not show enough benefit. Counted wins get paid, surprises get taxed, and the platforms in between get sold to whoever has patience. If you run a platform company, your buyer list just got shorter and richer.
🤝 Argenx Paid Cash for an Oral Peptide Engine
Argenx will buy Unnatural Products for $550 million upfront and up to approximately $1.15 billion in total, bringing an antibody company a platform for pills. ARGX | Unnatural Products (venture backed)
Unnatural Products designs orally delivered macrocyclic peptides by pairing AI guided design with massively parallel synthesis and direct to biology screening, aimed at targets that have resisted drugging. The two companies had worked together for more than two years, and BioPharma Dive reports argenx already held a minority stake. The Santa Cruz team, more than 50 people founded out of a UC Santa Cruz chemistry lab in 2016, stays put as argenx's macrocycle discovery hub. CEO Karen Massey called the capabilities "highly complementary to our antibody engineering." Argenx closed up 3.8%, in line with the sector.
The deal, piece by piece | Figure |
|---|---|
Upfront cash | $550 million |
Contingent value rights | Up to $595 million, per BioPharma Dive (release gives no split) |
Total potential value | Up to approximately $1.15 billion |
Upfront share of total | About 48% (our arithmetic) |
Expected close | By year end 2026 |
💉 Vir's Pivotal Win Got Paid
Vir closed at $13.645, up 11.8% in its first full session after ECLIPSE 1, nearly nine points ahead of a sector that rose 3.1%. VIR | GILD | MIRM
This was test one of the week's through line, and it graded for us: a counted pivotal result with a dated mid 2027 submission plan got paid, even without a buyer in sight. The asterisk is the tape, since the S&P rose 2.4% and everything lifted, but Vir's gap over the XBI is too wide to be the rally alone. Evercore ISI's Cory Kasimov, per BioPharma Dive, sees "potential to become a dominant front line product upon approval," while noting cross trial caveats against Gilead's Hepcludex and Mirum's brelovitug. Still missing from anything we could read: the serious adverse event count and the application type.
🧠 Novocure's Brain Metastases Trial Did Not Clear the Bar
The FDA sent Novocure a Not Approvable Letter on Optune Mya, saying the degree of clinical benefit was uncertain, and the stock fell 5.6% into a rising market. NVCR
Optune Mya delivers Tumor Treating Fields to adults with brain metastases from non small cell lung cancer after stereotactic radiation. MedTech Dive reports the pivotal METIS trial delayed brain progression against best supportive care but showed no difference on neurocognitive failure, overall survival or radiological response, which is exactly the gap "uncertain benefit" describes. The agency raised no safety concerns. Novocure wants a meeting to find a path that avoids a new trial and says there is no assurance one exists. Management had talked about approval by year end and a launch in early 2027.
💊 Veradermics Held Its Gains at a Year
Men who stayed on twice daily VDPHL01 gained 43.9 nonvellus hairs per square centimeter at month 12 in Study 302 Part B, and once daily patients gained 29.7. MANE
The extended release oral minoxidil kept 68.0% of twice daily patients rated improved or much improved, with no treatment related serious adverse events and no cardiac events of special interest. Because placebo patients crossed over at six months, there is no controlled comparison at a year, so read this as durability, not new efficacy. This is the 12 month Part B readout, not April's six month topline or October's Study 304. No filing date was given; the women's Study 306 reads out in the first half of 2027. Shares rose 3.7%, in line with the sector.
🧬 Zolgensma's Tumor Count Reached Nine
Novartis said nine people with SMA developed tumors after Zolgensma, two with evidence the AAV vector integrated into their DNA, out of about 6,000 treated, per BioPharma Dive. NVS
The statement came Thursday and the FDA followed Friday, saying it is investigating and evaluating whether regulatory action is appropriate, that benefits still outweigh risks for approved uses, and that the concern extends to the intrathecal Itvisma. We could not retrieve either statement directly, so every figure here is attributed. For anyone running an AAV program, integration evidence in two patients is the data point that matters; long term follow up just got more expensive to treat as a formality.
📋 Quick Hits
Rhythm had no statement on the reported AstraZeneca approach and we found no release on its expected $250 million facility draw (scope: searches Monday night). The stock closed at $113.94. RYTM
Regeneron hosts its MASH roundtable this morning at 8:30 am ET, the second test of the week's through line, after NEJM data showing liver fat reductions of 58% to 80% at week 36 for its CIDEB siRNA. REGN
Checked and quiet tonight: Vir's call commentary on the serious adverse event count and application type (transcript not retrievable). Our evening wire index came back empty, so late releases may surface Wednesday.
👀 What To Watch Today
Tue, Nov 10: MASH roundtable on the CIDEB siRNA data, 8:30 am ET, Regeneron
Wed, Nov 11: ALKIVIA late breaking oral at ACR Convergence, 9:15 am ET, argenx
Wed, Nov 11: R&D Day with Weltruza launch detail, Teva
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The argenx deal terms line by line, with what the release does and does not say about the milestones
Vir's first session against the sector, with the competitive set and analyst read attributed
What a Not Approvable Letter is and what the METIS data showed
The full 12 month Study 302 table across all four arms, and the Zolgensma disclosures dated and sourced
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 Who buys what the market will not fund: the argenx structure and the new map of platform exits
💊 The certainty premium, graded twice in one session, and what the rest of the week has to prove
📊 What "uncertain benefit" means for device sponsors, and why Zolgensma raises the bar on follow up
🎯 Plus the week's coming catalysts, with the full calendar returning in Friday's edition

